TOPICS

Tag: Acne Vulgaris

Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week Study

J Clin Aesthet Dermatol. 2021;14(4):43–48. by Angela Yen Moore, MD; Edward L. Lain, MD; Amy McMichael, MD; Leon Kircik, MD; Andrea L. Zaenglein, MD; Adelaide A. Hebert, MD; and Ayman Grada, MD Dr. Moore is with Arlington Center for Dermatology and Arlington Research Center in Arlington, Texas and Baylor University Medical Center in Dallas, Texas.

CONTINUE READING »

Osteoma Cutis and Calcinosis Cutis: “Similar but Different”

J Clin Aesthet Dermatol. 2020;13(11):28–31 by Dennis Niebel, MD; Sietske Poortinga, MD; and Jörg Wenzel, Prof, MD Drs. Niebel, Poortinga, and Wenzel are with the Department of Dermatology and Allergy, University Hospital Bonn at Bonn University in Bonn, Germany. FUNDING: No funding was provided for this study. DISCLOSURES: The authors have no conflicts of interest

CONTINUE READING »

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris

J Clin Aesthet Dermatol. 2019;12(10):16–23 by Linda Stein Gold, MD; Sunil Dhawan, MD; Jonathan Weiss, MD; Zoe Diana Draelos, MD; Herman Ellman, MD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Dhawan is with the Center for Dermatology Clinical Research, Inc., in Fremont, California. Dr. Weiss

CONTINUE READING »

Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short-Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1%

by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD

CONTINUE READING »